Compounds > carbostyril
Page last updated: 2024-08-17

carbostyril and Diabetes Mellitus, Type 2

carbostyril has been researched along with Diabetes Mellitus, Type 2 in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (15.79)18.2507
2000's7 (36.84)29.6817
2010's5 (26.32)24.3611
2020's4 (21.05)2.80

Authors

AuthorsStudies
Chen, Y; Cho, K; Elgendy, B; Ferguson, D; Finck, BN; Gill, LE; Griffett, K; Hegazy, L; Hodges, WT; Ilagan, MXG; Jarasvaraparn, C; McCommis, KS; Patti, GJ1
Bogár, L; Németh, M; Rozanovic, M; Ternák, G1
Donou, A; Kalantzi, S; Konsta, E; Loupa, CV; Meimeti, E; Voyatzoglou, ED1
Accili, D; Belvedere, S; Deroose, M; Diaz, B; Lee, SX; Lee, YK; Leibel, RL; Lin, HV1
Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Gasa, L; Giralt, M; Maroto, AF; Mateo, GM; Morón-Ros, S; Moure, R; Quesada-López, T; Villarroya, F; Villarroya, J1
Arnoldy, R; Curtis, J; Samaras, K1
Bae, JH; Chang, IH; Cho, IR; Chung, H; Chung, JM; Hwang, EC; Jung, SI; Kim, TH; Kim, YH; Kwon, DD; Lee, G; Lee, SJ; Min, SK; Na, YG; Son, H1
Aertgeerts, K; Asakawa, T; Banno, Y; Funami, M; Ikedo, K; Kataoka, O; Kosaka, T; Maezaki, H; Miyamoto, Y; Oi, S; Sasaki, M; Suzuki, N; Takeuchi, K; Tani, A; Tawada, M; Tsubotani, S; Yamamoto, Y; Yano, J1
Asahina, Y; Iwago, M; Iwane, A; Kohno, Y; Murakami, K; Okada, K; Seto, S; Shreder, KR; Terasawa, R; Yumoto, K1
Citrome, L; Volavka, J1
De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M2
Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM1
Perlis, RH1
Bushe, CJ; Leonard, BE1
Miura, Y; Nakano, H; Nakayama, M; Suzuki, S; Tsuchida, H; Yamada, K; Yoshida, S1
Iizuka, T; Nishikawa, T; Omura, M; Saito, I; Yoshida, S1
Dekens, J; Fodzo, E; Popesco, D; Tchaoussoff, J; Yagoubi, A1
Absher, PM; Dunkerley, HA; Jimmo, SL; Maurice, DH; Netherton, SJ; Palmer, D; Raymond, DR; Russell, JC; Sage, EH; Tilley, DG; Vernon, RB1

Reviews

3 review(s) available for carbostyril and Diabetes Mellitus, Type 2

ArticleYear
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
    Postgraduate medicine, 2004, Volume: 116, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain

2004
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
    The American journal of managed care, 2007, Volume: 13, Issue:7 Suppl

    Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain

2007
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:11

    Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines; Quinolones; Schizophrenia

2007

Trials

1 trial(s) available for carbostyril and Diabetes Mellitus, Type 2

ArticleYear
Short-term clinical trial of 1-(1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl)-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Possible effectiveness of the specific vasopressin V1 receptor antagonist for reducing albuminuria in p
    Arzneimittel-Forschung, 1996, Volume: 46, Issue:9

    Topics: Albuminuria; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Rate; Humans; Male; Middle Aged; Piperidines; Quinolones; Saline Solution, Hypertonic

1996

Other Studies

15 other study(ies) available for carbostyril and Diabetes Mellitus, Type 2

ArticleYear
Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice.
    The Journal of biological chemistry, 2022, Volume: 298, Issue:2

    Topics: Animals; Anion Transport Proteins; Diabetes Mellitus, Type 2; Diet; Glucose; Mice; Mice, Obese; Mitochondria; Mitochondrial Membrane Transport Proteins; Monocarboxylic Acid Transporters; Obesity; Pyruvic Acid; Quinolones

2022
Antibiotic Consumption Patterns in European Countries Might Be Associated with the Prevalence of Type 1 and 2 Diabetes.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dysbiosis; Europe; Humans; Penicillins; Prevalence; Quinolones; Tetracyclines

2022
Photosensitivity During Quinolone Therapy in Diabetic Foot Patients May Falsely Indicate Treatment Failure.
    The international journal of lower extremity wounds, 2023, Volume: 22, Issue:1

    Topics: Aged; Clindamycin; Diabetes Mellitus, Type 2; Diabetic Foot; Humans; Male; Middle Aged; Osteomyelitis; Quinolones; Treatment Failure; Ulcer

2023
FOXO1 inhibition synergizes with FGF21 to normalize glucose control in diabetic mice.
    Molecular metabolism, 2021, Volume: 49

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fibroblast Growth Factors; Forkhead Box Protein O1; Glucose; Hepatocytes; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Quinolones

2021
Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:6

    Topics: Adipose Tissue; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Diabetes Mellitus, Type 2; Drug Combinations; Endoplasmic Reticulum Stress; Fibroblast Growth Factors; Hep G2 Cells; HIV Infections; HIV Integrase Inhibitors; Humans; Klotho Proteins; Liver; Lopinavir; Maraviroc; Membrane Proteins; Muscle, Skeletal; Obesity; Oxidative Stress; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Thapsigargin; Tunicamycin

2018
The effects of antipsychotic switching on diabetes in chronic schizophrenia.
    Diabetic medicine : a journal of the British Diabetic Association, 2014, Volume: 31, Issue:3

    Topics: Antipsychotic Agents; Aripiprazole; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Weight Loss

2014
A prospective Korean multicenter study for infectious complications in patients undergoing prostate surgery: risk factors and efficacy of antibiotic prophylaxis.
    Journal of Korean medical science, 2014, Volume: 29, Issue:9

    Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Diabetes Mellitus, Type 2; Drug Resistance, Bacterial; Enterococcus; Escherichia coli; Humans; Klebsiella pneumoniae; Male; Middle Aged; Odds Ratio; Postoperative Complications; Prospective Studies; Prostatic Neoplasms; Quinolones; Risk Factors; Time Factors; Transurethral Resection of Prostate; Urinalysis; Urinary Tract Infections

2014
Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
    Bioorganic & medicinal chemistry, 2011, Aug-15, Volume: 19, Issue:16

    Topics: Administration, Oral; Animals; Blood Glucose; Caco-2 Cells; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Design; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Isoquinolines; Molecular Targeted Therapy; Peptides; Quinolones; Rats; Rats, Wistar; Structure-Activity Relationship

2011
Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3β (GSK-3β) inhibitors for type 2 diabetics.
    Bioorganic & medicinal chemistry, 2012, Feb-01, Volume: 20, Issue:3

    Topics: Animals; Diabetes Mellitus, Type 2; Drug Design; Glucose Tolerance Test; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Male; Mice; Models, Molecular; Quinolones; Spiro Compounds

2012
A case series: evaluation of the metabolic safety of aripiprazole.
    Schizophrenia bulletin, 2007, Volume: 33, Issue:3

    Topics: Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sex Factors; Treatment Outcome

2007
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:4

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain

2007
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:3

    Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors

2008
The effect of OPC-21268, an oral, nonpeptide arginine vasopressin V1 receptor antagonist, on a patient with congestive heart failure.
    Clinical nephrology, 1993, Volume: 40, Issue:1

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Blood Pressure; Diabetes Mellitus, Type 2; Female; Heart Failure; Heart Rate; Humans; Kidney Failure, Chronic; Piperidines; Quinolones

1993
[Peridural abscess complicating spinal anesthesia in a diabetic patient].
    Annales francaises d'anesthesie et de reanimation, 1997, Volume: 16, Issue:8

    Topics: 4-Quinolones; Abscess; Amikacin; Anesthesia, Spinal; Anti-Infective Agents; Diabetes Mellitus, Type 2; Disease Susceptibility; Drainage; Drug Therapy, Combination; Epidural Space; Fluoroquinolones; Humans; Laminectomy; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Oxacillin; Pefloxacin; Postoperative Complications; Povidone-Iodine; Punctures; Quinolones; Spinal Diseases; Staphylococcal Infections

1997
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease.
    Diabetes, 2002, Volume: 51, Issue:4

    Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Aorta; Cell Membrane; Cell Movement; Cells, Cultured; Colforsin; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytosol; Diabetes Mellitus, Type 2; Hydrolysis; Muscle, Smooth, Vascular; Obesity; Phenotype; Phosphodiesterase Inhibitors; Quinolones; Rats; Rats, Mutant Strains

2002